Advertisement

Topics

Lilly’s novel migraine drug hits PhIII targets

03:54 EDT 7 Aug 2017 | PharmaTimes

Eli Lilly’s investigational, oral, first-in-class molecule lasmiditan has hit key targets a late-stage trial assessing its safety and efficacy as a treatment for acute migraine, raising hopes for a new approach to managing the condition.

Original Article: Lilly’s novel migraine drug hits PhIII targets

NEXT ARTICLE

More From BioPortfolio on "Lilly’s novel migraine drug hits PhIII targets"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...